List of works - Jason Madore

ARID1A mutations in endometriosis-associated ovarian carcinomas

scientific article

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment

scientific article published on 29 March 2018

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function

scientific article published on 20 March 2019

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

scientific article

Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases

scientific article published on 20 May 2015

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

scientific article published on 16 May 2017

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

scientific article

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

scientific article published on 9 March 2016

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

article

Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype

scientific article

RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells

scientific article published on 12 January 2018

Recurrent inactivating RASA2 mutations in melanoma

scientific article published on 26 October 2015

Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases.

scientific article published on 27 October 2017

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

scientific article published on 26 June 2017

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes

scientific article

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma

scientific article published on 28 April 2020

List of works by Jason Madore

ARID1A mutations in endometriosis-associated ovarian carcinomas

CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment

CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype

RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells

Recurrent inactivating RASA2 mutations in melanoma

Reply to comment on: Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (< 0.1 mm) Sentinel Lymph Node Metastases.

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes

Tumor CD155 expression is associated with resistance to anti-PD1 immunotherapy in metastatic melanoma